These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 13678484)

  • 1. Stroke prevention: is it possible? If so, which antihypertensive agent should be used?
    Kim S
    Curr Med Res Opin; 2003; 19(5):442-4. PubMed ID: 13678484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Organ protection by angiotensin II receptor blockers].
    Kumagai H; Onami T; Takimoto C; Iigaya K; Saruta T
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():569-73. PubMed ID: 15171437
    [No Abstract]   [Full Text] [Related]  

  • 3. Neurological protection provided by candesartan: reviewing the latest study results.
    Leys D
    Curr Med Res Opin; 2003; 19(5):445-8. PubMed ID: 13678485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Of millimeterology and cannibalism: comparative antihypertensive efficacy of angiotensin receptor blockers.
    Messerli FH
    Am Heart J; 2003 Oct; 146(4):568-9. PubMed ID: 14564307
    [No Abstract]   [Full Text] [Related]  

  • 5. Angiotensin and cerebral blood flow.
    Saavedra JM; Nishimura Y
    Cell Mol Neurobiol; 1999 Oct; 19(5):553-73. PubMed ID: 10384255
    [No Abstract]   [Full Text] [Related]  

  • 6. [AT1 blocker therapy of hypertension in seniors. Added protection for cerebral blood vessels?].
    MMW Fortschr Med; 2003 Jan; 145(1-2):53. PubMed ID: 12638442
    [No Abstract]   [Full Text] [Related]  

  • 7. [Lowering blood pressure with sartans. Are there differences?].
    MMW Fortschr Med; 2002 Nov; 144(47):63. PubMed ID: 12532530
    [No Abstract]   [Full Text] [Related]  

  • 8. [Protective vascular effect of angiotensin receptor blocker (ARB)].
    Yamakado M
    Nihon Rinsho; 2002 Oct; 60(10):2020-7. PubMed ID: 12397701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of angiotensin II receptor antagonist on insulin sensitivity and sympathetic activity in spontaneously hypertensive rats].
    Sasaki K; Kushiro T; Nakagawa S; Kanmatsuse K
    Nihon Jinzo Gakkai Shi; 1999 Oct; 41(7):692-6. PubMed ID: 10572394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choice of treatment: outcomes and treatment goals.
    Temple RJ
    Am Heart J; 2003 Oct; 146(4):565-7. PubMed ID: 14564306
    [No Abstract]   [Full Text] [Related]  

  • 11. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
    Cice G; Ferrara L; Tagliamonte E; Russo PE; Di Benedetto A; Iacono A
    Cardiologia; 1999 Dec; 44(12):1071-6. PubMed ID: 10687258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats.
    Stier CT; Adler LA; Levine S; Chander PN
    J Hypertens Suppl; 1993 Apr; 11(3):S37-42. PubMed ID: 8315518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension.
    Yu Y; Fukuda N; Yao EH; Matsumoto T; Kobayashi N; Suzuki R; Tahira Y; Ueno T; Matsumoto K
    Am J Hypertens; 2008 Jan; 21(1):72-7. PubMed ID: 18091747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-AT(1)-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil.
    Dalmay F; Mazouz H; Allard J; Pesteil F; Achard JM; Fournier A
    J Renin Angiotensin Aldosterone Syst; 2001 Jun; 2(2):103-6. PubMed ID: 11881107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
    MMW Fortschr Med; 2003 Apr; 145(15):62. PubMed ID: 15104271
    [No Abstract]   [Full Text] [Related]  

  • 18. Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.
    Díez J
    Clin Ther; 2006 Jun; 28(6):832-48. PubMed ID: 16860167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
    Papademetriou V; Farsang C; Elmfeldt D; Hofman A; Lithell H; Olofsson B; Skoog I; Trenkwalder P; Zanchetti A;
    J Am Coll Cardiol; 2004 Sep; 44(6):1175-80. PubMed ID: 15364316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats.
    Inada Y; Wada T; Shibouta Y; Ojima M; Sanada T; Ohtsuki K; Itoh K; Kubo K; Kohara Y; Naka T
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1540-7. PubMed ID: 8138966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.